Oppenheimer Maintains Outperform on Opus Genetics, Raises Price Target to $20
Oppenheimer analyst Andreas Argyrides maintains Opus Genetics (NASDAQ:IRD) with a Outperform and raises the price target from $10 to $20.
A big investment company's expert thinks Opus Genetics is a good company and believes it could be worth twice as much money in the future. This shows they feel more confident about the company than they did before.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.